Spyre Therapeutics (SYRE) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$11.2 million.
- Spyre Therapeutics' Income towards Parent Company rose 8379.93% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 3068.05%. This contributed to the annual value of -$208.0 million for FY2024, which is 3859.97% up from last year.
- Per Spyre Therapeutics' latest filing, its Income towards Parent Company stood at -$11.2 million for Q3 2025, which was up 8379.93% from -$36.7 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Income towards Parent Company registered a high of -$6.8 million during Q2 2021, and its lowest value of -$217.1 million during Q2 2023.
- For the 5-year period, Spyre Therapeutics' Income towards Parent Company averaged around -$41.5 million, with its median value being -$24.4 million (2022).
- Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 87245.44% in 2023, then skyrocketed by 8379.93% in 2025.
- Spyre Therapeutics' Income towards Parent Company (Quarter) stood at -$20.4 million in 2021, then rose by 7.94% to -$18.8 million in 2022, then plummeted by 235.67% to -$63.2 million in 2023, then grew by 10.9% to -$56.3 million in 2024, then surged by 80.14% to -$11.2 million in 2025.
- Its Income towards Parent Company was -$11.2 million in Q3 2025, compared to -$36.7 million in Q2 2025 and -$44.8 million in Q1 2025.